Zentek Business Summary

Zentek Ltd. (ZTEK) is an intellectual property (IP) development and commercialization company specializing in graphene-based nanomaterials and nanotechnology-enabled solutions. The company generates revenue through a hybrid model of product sales, licensing, and a newly adopted "development-on-demand" contract R&D framework, where it partners with industrial leaders to solve regulatory and performance challenges using its materials IP. Its operations are concentrated into three core platforms: ZenGUARD, a patented antimicrobial coating for HVAC filters and medical PPE; Albany Graphite, which produces high-purity graphene for battery anodes and nuclear applications; and Triera Biosciences, focused on aptamer-based diagnostic and therapeutic technologies. Zentek competes in the advanced materials and specialty chemicals sectors against firms such as Alto Ingredients, ARQ, and HydroGraph Clean Power, positioning itself as a high-growth bridge between laboratory-scale nanotechnology and industrial-scale commercial application. Leadership is currently spearheaded by CEO Mohammed (Moe) Jiwan, who took the helm in December 2025 bringing over 20 years of experience in scaling high-growth ventures across the healthcare and life sciences sectors. He is supported by CFO Wendy Ford, who previously served as interim CEO and has been instrumental in the company’s recent strategic reset and cost-optimization initiatives. The Board of Directors is led by Chairman John Snisarenko, a commercialization expert with a deep pedigree in the pharmaceutical industry, including senior roles at Bausch Health and Sanofi. Other key board members include Eric Wallman, Matt Fontes, and Pete Gettinby, who provide oversight in audit, modular building science, and international environmental engineering. This management team is focused on transitioning Zentek from a research-heavy entity into a disciplined, commercial-stage enterprise with a 24-month roadmap for its primary technology verticals.